Condition: Immune Thrombocytopenia (ITP) · Sponsor: Eli Lilly and Company
The purpose of the phase 1 part of this study was to evaluate how well pirtobrutinib is tolerated and what side effects may occur. The phase 2 part of the study will further investigate efficacy and safety of multiple pirtobrutinib dosages versus placebo. The study drug will be administered orally in participants with Primary Immune Thrombocytopenia (ITP). Blood tests will be performed to check how much pirtobrutinib gets into the bloodstream and how long it takes the body to eliminate it. The study will last up to approximately 16 weeks for phase 1 dose-escalation and 28 weeks for phase 2 dose-optimization, excluding screening.
This description comes directly from the study's public registry record.
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or · 1-317-615-4559 · LillyTrials@Lilly.com
Physicians interested in becoming principal investigators please contact · clinical_inquiry_hub@lilly.com
Always discuss trial participation with your own doctor first.
| USC Norris Comprehensive Cancer Center | Los Angeles, California, United States | Recruiting |
| Stanford University | Stanford, California, United States | Not Yet Recruiting |
| MedStar Georgetown University Hospital | Washington D.C., District of Columbia, United States | Recruiting |
| University of Miami Hospital and Clinics Sylvester Comprehensive Cancer Center | Miami, Florida, United States | Not Yet Recruiting |
| Bleeding and Clotting Disorders Institute | Peoria, Illinois, United States | Not Yet Recruiting |
| Ochsner Clinic Foundation | New Orleans, Louisiana, United States | Recruiting |
| Mayo Clinic | Rochester, Minnesota, United States | Not Yet Recruiting |
| Clinical Research Alliance | Westbury, New York, United States | Recruiting |
| Texas Oncology - Central South | Austin, Texas, United States | Not Yet Recruiting |
| MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| Texas Oncology Gulf Coast | The Woodlands, Texas, United States | Not Yet Recruiting |
| Nanfang Hospital of Southern Medical University | Guangzhou, China | Not Yet Recruiting |
+ 33 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06721013